MCID: HRN003
MIFTS: 41

Heroin Dependence

Categories: Mental diseases

Aliases & Classifications for Heroin Dependence

MalaCards integrated aliases for Heroin Dependence:

Name: Heroin Dependence 12 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9976
MeSH 44 D006556
NCIt 50 C34694
UMLS 73 C0019337

Summaries for Heroin Dependence

Disease Ontology : 12 An opiate dependence that involves the continued use of heroin despite problems related to use of the substance.

MalaCards based summary : Heroin Dependence is related to antisocial personality disorder and personality disorder. An important gene associated with Heroin Dependence is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Amphetamine addiction and Microglia Activation During Neuroinflammation: Steady-State Microglia. The drugs Buprenorphine and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 76 Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or... more...

Related Diseases for Heroin Dependence

Diseases related to Heroin Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 30.3 ANKK1 DRD2
2 personality disorder 30.2 ANKK1 BDNF DRD2 DRD4
3 morphine dependence 29.9 OPRD1 OPRM1
4 mood disorder 29.7 BDNF DRD2 DRD4
5 major depressive disorder 29.7 BDNF DRD2 DRD4
6 schizophrenia 29.7 BDNF DRD2 DRD4 MIAT
7 alcohol abuse 29.5 ANKK1 BDNF DRD2 DRD4
8 substance abuse 29.5 BDNF DRD2 DRD4 MIAT
9 autism 29.4 AUTS2 BDNF DRD2 DRD4
10 cocaine dependence 29.4 DRD2 OPRD1 OPRM1 PDYN
11 substance dependence 29.4 BDNF DRD2 DRD4 OPRD1 OPRM1
12 attention deficit-hyperactivity disorder 29.3 ANKK1 BDNF DRD2 DRD4 OPRM1
13 disease of mental health 29.2 BDNF DRD2 DRD4 OPRM1 PDYN
14 depression 10.2
15 early-onset schizophrenia 10.2 BDNF DRD2
16 tic disorder 10.2 DRD2 DRD4
17 delusional disorder 10.2 DRD2 DRD4
18 neonatal abstinence syndrome 10.2 OPRD1 OPRM1
19 pathological gambling 10.2 DRD2 DRD4
20 oppositional defiant disorder 10.2 DRD2 DRD4
21 traumatic brain injury 10.2 BDNF DRD2
22 brain injury 10.1 BDNF DRD2
23 separation anxiety disorder 10.1 DRD4 OPRM1
24 taqi polymorphism 10.1 ANKK1 DRD2
25 alexithymia 10.1 ANKK1 DRD2
26 alpha thalassemia-intellectual disability syndrome type 1 10.1 BDNF DRD4
27 hepatitis 10.1
28 borderline personality disorder 10.1
29 migraine without aura 10.1 DRD2 DRD4
30 withdrawal disorder 10.1 OPRM1 PDYN
31 paranoid schizophrenia 10.1 BDNF MIAT
32 opioid addiction 10.1 DRD2 OPRD1 OPRM1
33 gilles de la tourette syndrome 10.1 BDNF DRD2 DRD4
34 psychotic disorder 10.0 BDNF DRD2 DRD4
35 tobacco addiction 10.0 ANKK1 DRD2 OPRM1
36 conduct disorder 10.0 DRD2 DRD4
37 pain agnosia 10.0 OPRM1 PDYN
38 agnosia 10.0 OPRM1 PDYN
39 impulse control disorder 10.0 ANKK1 DRD2 DRD4
40 sexual disorder 10.0
41 post-traumatic stress disorder 10.0
42 generalized anxiety disorder 10.0 BDNF DRD2
43 amnestic disorder 10.0 BDNF PDYN
44 opioid abuse 10.0 DRD2 OPRM1 PDYN
45 hepatitis c virus 9.9
46 hepatitis c 9.9
47 human immunodeficiency virus infectious disease 9.9
48 opiate dependence 9.8 DRD2 OPRD1 OPRM1 PDYN
49 specific developmental disorder 9.8 BDNF DRD4 OPRM1 PDYN
50 obsessive-compulsive disorder 9.8 BDNF DRD2 DRD4 PDYN

Graphical network of the top 20 diseases related to Heroin Dependence:



Diseases related to Heroin Dependence

Symptoms & Phenotypes for Heroin Dependence

MGI Mouse Phenotypes related to Heroin Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 AUTS2 BDNF DRD2 DRD4 OPRD1 OPRM1
2 nervous system MP:0003631 9.5 AUTS2 BDNF DRD2 DRD4 OPRD1 OPRM1
3 no phenotypic analysis MP:0003012 9.1 AUTS2 BDNF DRD2 OPRD1 OPRM1 PDYN

Drugs & Therapeutics for Heroin Dependence

Drugs for Heroin Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 93-14-1 3516
3
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 76-99-3 4095
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
5
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
6
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
7
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
8
Heroin Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 561-27-3 5462328
9 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antitussive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Narcotics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Serotonin Agents Phase 4,Phase 3
19 Opiate Alkaloids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Tranquilizing Agents Phase 4,Phase 3,Phase 1
21 Psychotropic Drugs Phase 4,Phase 3,Phase 1
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Anxiety Agents Phase 4
26
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
27
Mirtazapine Approved Phase 3 61337-67-5, 85650-52-8 4205
28
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
29
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
30
Mianserin Approved, Investigational Phase 3 24219-97-4 4184
31
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
32
Morphine Approved, Investigational Phase 3,Phase 2,Phase 1 57-27-2 5288826
33
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
34
Hydromorphone Approved, Illicit Phase 3 466-99-9 5284570
35
Clonidine Approved Phase 3,Phase 1 4205-90-7 2803
36
Imidacloprid Vet_approved Phase 2, Phase 3 105827-78-9 86418
37 Sympathomimetics Phase 3
38 Autonomic Agents Phase 3,Phase 1,Phase 2
39 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
40 Serotonin Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42 Dopamine Uptake Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
43 Histamine Antagonists Phase 3
44 Antidepressive Agents Phase 3
45
Histamine Phosphate Phase 3 51-74-1 65513
46 Antidepressive Agents, Second-Generation Phase 3
47 Adrenergic alpha-Antagonists Phase 3,Phase 1
48 Central Nervous System Stimulants Phase 3,Phase 1,Phase 2
49 Adrenergic Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Adrenergic Antagonists Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
2 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
3 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4 Buspirone
5 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
6 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
7 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
8 Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
9 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541513 Phase 3 paliparidone
10 An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541500 Phase 3 Minocycline
11 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Completed NCT00476242 Phase 2, Phase 3 Vivitrol;memantine
12 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Completed NCT01760473 Phase 3 Intranasal challenge drug
13 Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Completed NCT00577408 Phase 3 depot naltrexone;Oral Naltrexone
14 Study Comparing Liquid and Tablet Buprenorphine Formulations - 5 Completed NCT00000302 Phase 3 Buprenorphine
15 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Completed NCT00684554 Phase 2, Phase 3 Buprenorphine
16 Directly Administered HIV Therapy in Methadone Clinics Completed NCT00279110 Phase 2, Phase 3
17 Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Completed NCT01447212 Phase 3 Hydromorphone, Injectable;Diacetylmorphine, injectable;Hydromorphone, liquid oral;Diacetylmorphine, liquid oral
18 Buprenorphine for Prisoners Completed NCT00574067 Phase 3 Buprenorphine +OTP;Buprenorphine +CHC;Counseling +OTP;Counseling +CHC
19 Methadone Maintenance for Prisoners Completed NCT00378079 Phase 3 Counseling + Transfer;Counseling + Methadone
20 Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Completed NCT00015171 Phase 3 Buprenorphine/naloxone
21 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3 Buprenorphine/naloxone
22 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3 Buprenorphine/naloxone
23 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
24 ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence Completed NCT00678418 Phase 3 VIVITROL® 380 mg;Placebo
25 Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals Recruiting NCT03711318 Phase 3 Buprenorphine/naloxone
26 The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention Recruiting NCT02440152 Phase 2, Phase 3
27 Addiction Treatment in Russia: Oral vs. Naltrexone Implant Active, not recruiting NCT00218426 Phase 2, Phase 3 naltrexone implant;Oral naltrexone;placebo oral and placebo implant
28 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
29 Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India Withdrawn NCT00709007 Phase 2, Phase 3
30 Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
31 Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 Unknown status NCT00023283 Phase 2 Buprenorphine
32 Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Completed NCT00218127 Phase 2 Levoacetyl Methadol;Levoacetyl Methadol;Levoacetyl Methadol
33 Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Completed NCT00332228 Phase 2 depot naltrexone;BNT
34 Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts Completed NCT00142948 Phase 2 Naltrexone;Placebo
35 Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Completed NCT00238914 Phase 2 Naltrexone
36 Effects of Dynorphin 1-13 on Heroin Addiction - 1 Completed NCT00000244 Phase 2 Dynorphin 1 - 13
37 Study of Computer-Based Treatment for Drug Dependence Completed NCT01315184 Phase 2
38 Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Completed NCT00000211 Phase 2 Buprenorphine
39 Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Completed NCT00000210 Phase 2 Buprenorphine
40 Addition of Naltrexone to Methadone Taper Completed NCT00135759 Phase 2 Naltrexone;Placebo comparator;naltrexone;naltrexone
41 A Laboratory Model for Heroin Abuse Medications - 8 Completed NCT00000273 Phase 2 opiates
42 Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Completed NCT01863251 Phase 2 Atomoxetine
43 Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX Completed NCT01101815 Phase 2 Oral Naltrexone;Naltrexone Implant
44 The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 Completed NCT00158288 Phase 2
45 Pioglitazone for Heroin and for Nicotine Dependence Terminated NCT01395797 Phase 1, Phase 2 PIO;Placebo
46 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1 Withdrawn NCT00000326 Phase 2 Heroin Dependence
47 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2 Withdrawn NCT00000327 Phase 2 Heroin Dependence
48 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6 Withdrawn NCT00000331 Phase 2 Test Drug;Placebo Drug
49 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Withdrawn NCT00000330 Phase 2 Opioid-Related Disorders
50 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4 Withdrawn NCT00000329 Phase 2 Opioid-Related Disorders

Search NIH Clinical Center for Heroin Dependence

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: heroin dependence

Genetic Tests for Heroin Dependence

Anatomical Context for Heroin Dependence

MalaCards organs/tissues related to Heroin Dependence:

41
Brain, Testes, Cortex, Pituitary, Prefrontal Cortex, Spinal Cord

Publications for Heroin Dependence

Articles related to Heroin Dependence:

(show top 50) (show all 228)
# Title Authors Year
1
OPRD1 gene affects disease vulnerability and environmental stress in patients with heroin dependence in Han Chinese. ( 30171993 )
2019
2
The long-term impact of post traumatic stress disorder on recovery from heroin dependence. ( 29706174 )
2018
3
Association between stress pathway gene (CRHR1as^CRHBP) polymorphisms and heroin dependence. ( 29853227 )
2018
4
Opioid Receptors Gene Polymorphism and Heroin Dependence in Iran. ( 29967669 )
2018
5
A 35.8 kilobases haplotype spanning ANKK1 and DRD2 is associated with heroin dependence in Han Chinese males. ( 29550268 )
2018
6
Altered gray matter volume and disrupted functional connectivity of dorsolateral prefrontal cortex in men with heroin dependence. ( 29582514 )
2018
7
Risk of Heroin Dependence in Newly Incident Heroin Users. ( 29847618 )
2018
8
GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence. ( 30060048 )
2018
9
NGF gene polymorphisms are not associated with heroin dependence in a Taiwanese male population. ( 30070410 )
2018
10
Prevalence of Deliberate Self-harm Among Chinese Patients With Heroin Dependence: A Meta-Analysis. ( 30072926 )
2018
11
Genetic association analyses and meta-analysis of Dynorphin-Kappa Opioid system potential functional variants with heroin dependence. ( 30138645 )
2018
12
Treatment of an HIV-affected adolescent with heroin dependence in a low-income country: A clinical case study from Zambia. ( 30505923 )
2018
13
Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese. ( 28692418 )
2017
14
Neural Correlates of Drug-Related Attentional Bias in Heroin Dependence. ( 29410620 )
2017
15
Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. ( 28473157 )
2017
16
DRD2 and ANKK1 genes associate with late-onset heroin dependence in men. ( 28854834 )
2017
17
A novel inhibitor of endocannabinoid catabolic enzymes sheds light on behind the scene interplay between chronic pain, analgesic tolerance, and heroin dependence. ( 27890603 )
2017
18
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. ( 28371689 )
2017
19
Influence of Duration of Heroin Dependence on Humoral Immunologic Indicators. ( 27610581 )
2016
20
Association between dopamine D2 receptor gene polymorphisms and the risk of heroin dependence. ( 27819741 )
2016
21
Genome-Wide Association of Heroin Dependence in Han Chinese. ( 27936112 )
2016
22
Polymorphisms in the 5-hydroxytryptamine receptor 3B gene are associated with heroin dependence in the Chinese Han population. ( 27773795 )
2016
23
Heroin craving and its correlations with clinical outcome indicators in people with heroin dependence receiving methadone maintenance treatment. ( 26773990 )
2016
24
Association between serotonin transporter gene polymorphisms and heroin dependence: a meta-analytic study. ( 27942217 )
2016
25
Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. ( 27664554 )
2016
26
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. ( 25781230 )
2015
27
Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. ( 25619110 )
2015
28
QTc Prolongation in Veterans With Heroin Dependence on Methadone Maintenance Treatment. ( 26097838 )
2015
29
Serum brain-derived neurotrophic factor levels and psychotic symptoms in heroin dependence. ( 26343470 )
2015
30
Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. ( 25484035 )
2015
31
Single-nucleotide polymorphisms in dopamine receptor D1 are associated with heroin dependence but not impulsive behavior. ( 25966176 )
2015
32
Acknowledging Heroin Dependence as a Preventable Pediatric Chronic Medical Condition. ( 26163081 )
2015
33
Association between variable number of tandem repeats (VNTR) polymorphism in the promoter region of monoamine oxidase A (MAOA) gene and susceptibility to heroin dependence. ( 26298506 )
2015
34
MalmAP Treatment Referral and Intervention Study (MATRIS)-effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. ( 26613636 )
2015
35
Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. ( 25452049 )
2015
36
Evidence for the contribution of genetic variations in regulator of G protein signaling 9 to the genetic susceptibility of heroin dependence. ( 25591550 )
2015
37
GABRB2 Haplotype Association with Heroin Dependence in Chinese Population. ( 26561861 )
2015
38
Comparative gene expression profiling analysis of lymphoblastoid cells reveals neuron-specific enolase gene (ENO2) as a susceptibility gene of heroin dependence. ( 21995595 )
2014
39
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. ( 24725468 )
2014
40
Association analysis of GABRB3 promoter variants with heroin dependence. ( 25025424 )
2014
41
Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. ( 25048760 )
2014
42
Factors associated with one year retention to methadone maintenance treatment program among patients with heroin dependence in China. ( 24565169 )
2014
43
[Association study of CNR1, GAD1 and BDNF polymorphisms with male heroin dependence in the Dai population in Yunnan]. ( 25252306 )
2014
44
Excessive suicide mortality and risk factors for suicide among patients with heroin dependence. ( 25456334 )
2014
45
Chronic heroin dependence leading to adrenal insufficiency. ( 25221675 )
2014
46
Comparative study of the perceived quality of life of patients in treatment for cocaine and heroin dependence in Spain: differences by gender and time in treatment. ( 24712297 )
2014
47
Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population. ( 24498053 )
2014
48
The effect of heroin dependence on resumption of heroin self-administration in rats. ( 24613630 )
2014
49
Gender sameness and difference in recovery from heroin dependence: A qualitative exploration. ( 24041800 )
2014
50
Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. ( 22500942 )
2014

Variations for Heroin Dependence

Expression for Heroin Dependence

Search GEO for disease gene expression data for Heroin Dependence.

Pathways for Heroin Dependence

Pathways related to Heroin Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.87 BDNF DRD2 PDYN
2 10.61 BDNF DRD2

GO Terms for Heroin Dependence

Cellular components related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of presynaptic membrane GO:0099056 9.43 DRD2 OPRD1 OPRM1
2 integral component of postsynaptic membrane GO:0099055 9.37 DRD2 OPRM1
3 axon terminus GO:0043679 9.33 DRD2 OPRD1 PDYN
4 dendrite membrane GO:0032590 9.32 OPRD1 OPRM1
5 dendrite GO:0030425 9.02 BDNF DRD2 DRD4 OPRM1 PDYN
6 spine apparatus GO:0097444 8.96 OPRD1 OPRM1

Biological processes related to Heroin Dependence according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.92 DRD2 DRD4 OPRD1 OPRM1 PDYN
2 synapse assembly GO:0007416 9.62 BDNF DRD2
3 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.61 OPRD1 OPRM1
4 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.61 OPRD1 OPRM1
5 neuropeptide signaling pathway GO:0007218 9.61 OPRD1 OPRM1 PDYN
6 adult locomotory behavior GO:0008344 9.6 DRD4 OPRD1
7 response to cocaine GO:0042220 9.59 DRD2 OPRM1
8 response to amphetamine GO:0001975 9.58 DRD2 DRD4
9 regulation of sensory perception of pain GO:0051930 9.58 OPRD1 OPRM1
10 response to morphine GO:0043278 9.57 DRD2 OPRM1
11 positive regulation of neurogenesis GO:0050769 9.56 DRD2 OPRM1
12 arachidonic acid secretion GO:0050482 9.55 DRD2 DRD4
13 eating behavior GO:0042755 9.54 OPRD1 OPRM1
14 behavioral response to cocaine GO:0048148 9.51 DRD2 DRD4
15 dopamine receptor signaling pathway GO:0007212 9.49 DRD2 DRD4
16 negative regulation of protein secretion GO:0050709 9.48 DRD2 DRD4
17 dopamine metabolic process GO:0042417 9.46 DRD2 DRD4
18 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.43 DRD4 OPRD1 OPRM1
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.4 DRD2 DRD4
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.37 DRD2 DRD4
21 opioid receptor signaling pathway GO:0038003 9.32 OPRD1 OPRM1
22 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.16 DRD2 DRD4
23 response to histamine GO:0034776 8.96 DRD2 DRD4
24 behavioral response to ethanol GO:0048149 8.8 DRD2 DRD4 OPRM1

Molecular functions related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.67 DRD2 DRD4 OPRD1 OPRM1
2 neuropeptide binding GO:0042923 9.32 OPRD1 OPRM1
3 dopamine binding GO:0035240 9.26 DRD2 DRD4
4 opioid receptor activity GO:0004985 9.16 OPRD1 OPRM1
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD2 DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 8.62 DRD2 DRD4

Sources for Heroin Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....